In the HER2-positive GC subgroup, 7 of the 11 patients (63.5%) who received this regimen as 2nd-line treatment achieved a PR, 5 of them (45.5%) achieved a confirmed PR. This evidence concerns the gene ERBB2 and gastric cancer.